131 related articles for article (PubMed ID: 26189030)
1. Exploration of the nicotinamide-binding site of the tankyrases, identifying 3-arylisoquinolin-1-ones as potent and selective inhibitors in vitro.
Paine HA; Nathubhai A; Woon EC; Sunderland PT; Wood PJ; Mahon MF; Lloyd MD; Thompson AS; Haikarainen T; Narwal M; Lehtiö L; Threadgill MD
Bioorg Med Chem; 2015 Sep; 23(17):5891-908. PubMed ID: 26189030
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design, synthesis and evaluation in vitro of arylnaphthyridinones, arylpyridopyrimidinones and their tetrahydro derivatives as inhibitors of the tankyrases.
Kumpan K; Nathubhai A; Zhang C; Wood PJ; Lloyd MD; Thompson AS; Haikarainen T; Lehtiö L; Threadgill MD
Bioorg Med Chem; 2015 Jul; 23(13):3013-32. PubMed ID: 26026769
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships of 2-arylquinazolin-4-ones as highly selective and potent inhibitors of the tankyrases.
Nathubhai A; Haikarainen T; Hayward PC; Muñoz-Descalzo S; Thompson AS; Lloyd MD; Lehtiö L; Threadgill MD
Eur J Med Chem; 2016 Aug; 118():316-27. PubMed ID: 27163581
[TBL] [Abstract][Full Text] [Related]
4. Design and Discovery of 2-Arylquinazolin-4-ones as Potent and Selective Inhibitors of Tankyrases.
Nathubhai A; Wood PJ; Lloyd MD; Thompson AS; Threadgill MD
ACS Med Chem Lett; 2013 Dec; 4(12):1173-7. PubMed ID: 24900625
[TBL] [Abstract][Full Text] [Related]
5. Discovery and Optimization of 2-Arylquinazolin-4-ones into a Potent and Selective Tankyrase Inhibitor Modulating Wnt Pathway Activity.
Buchstaller HP; Anlauf U; Dorsch D; Kuhn D; Lehmann M; Leuthner B; Musil D; Radtki D; Ritzert C; Rohdich F; Schneider R; Esdar C
J Med Chem; 2019 Sep; 62(17):7897-7909. PubMed ID: 31381853
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of a Tankyrase-Axin complex and its implications for Axin turnover and Tankyrase substrate recruitment.
Morrone S; Cheng Z; Moon RT; Cong F; Xu W
Proc Natl Acad Sci U S A; 2012 Jan; 109(5):1500-5. PubMed ID: 22307604
[TBL] [Abstract][Full Text] [Related]
7. Tankyrase Inhibitors Stimulate the Ability of Tankyrases to Bind Axin and Drive Assembly of β-Catenin Degradation-Competent Axin Puncta.
Martino-Echarri E; Brocardo MG; Mills KM; Henderson BR
PLoS One; 2016; 11(3):e0150484. PubMed ID: 26930278
[TBL] [Abstract][Full Text] [Related]
8. Structural and functional analysis of parameters governing tankyrase-1 interaction with telomeric repeat-binding factor 1 and GDP-mannose 4,6-dehydratase.
Eisemann T; Langelier MF; Pascal JM
J Biol Chem; 2019 Oct; 294(40):14574-14590. PubMed ID: 31375564
[TBL] [Abstract][Full Text] [Related]
9. The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.
Okada-Iwasaki R; Takahashi Y; Watanabe Y; Ishida H; Saito J; Nakai R; Asai A
Mol Cancer Ther; 2016 Jul; 15(7):1525-34. PubMed ID: 27196752
[TBL] [Abstract][Full Text] [Related]
10. The Poly(ADP-ribose) Polymerase Enzyme Tankyrase Antagonizes Activity of the β-Catenin Destruction Complex through ADP-ribosylation of Axin and APC2.
Croy HE; Fuller CN; Giannotti J; Robinson P; Foley AVA; Yamulla RJ; Cosgriff S; Greaves BD; von Kleeck RA; An HH; Powers CM; Tran JK; Tocker AM; Jacob KD; Davis BK; Roberts DM
J Biol Chem; 2016 Jun; 291(24):12747-12760. PubMed ID: 27068743
[TBL] [Abstract][Full Text] [Related]
11. 2-Phenylquinazolinones as dual-activity tankyrase-kinase inhibitors.
Nkizinkiko Y; Desantis J; Koivunen J; Haikarainen T; Murthy S; Sancineto L; Massari S; Ianni F; Obaji E; Loza MI; Pihlajaniemi T; Brea J; Tabarrini O; Lehtiö L
Sci Rep; 2018 Jan; 8(1):1680. PubMed ID: 29374194
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for tankyrase-RNF146 interaction reveals noncanonical tankyrase-binding motifs.
DaRosa PA; Klevit RE; Xu W
Protein Sci; 2018 Jun; 27(6):1057-1067. PubMed ID: 29604130
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of selective inhibition of human tankyrases.
Narwal M; Venkannagari H; Lehtiö L
J Med Chem; 2012 Feb; 55(3):1360-7. PubMed ID: 22233320
[TBL] [Abstract][Full Text] [Related]
14. Tankyrases as drug targets.
Lehtiö L; Chi NW; Krauss S
FEBS J; 2013 Aug; 280(15):3576-93. PubMed ID: 23648170
[TBL] [Abstract][Full Text] [Related]
15. Nutritional energy stimulates NAD+ production to promote tankyrase-mediated PARsylation in insulinoma cells.
Zhong L; Yeh TY; Hao J; Pourtabatabaei N; Mahata SK; Shao J; Chessler SD; Chi NW
PLoS One; 2015; 10(4):e0122948. PubMed ID: 25876076
[TBL] [Abstract][Full Text] [Related]
16. Evaluation and Structural Basis for the Inhibition of Tankyrases by PARP Inhibitors.
Haikarainen T; Narwal M; Joensuu P; Lehtiö L
ACS Med Chem Lett; 2014 Jan; 5(1):18-22. PubMed ID: 24900770
[TBL] [Abstract][Full Text] [Related]
17. Evidence for tankyrases as antineoplastic targets in lung cancer.
Busch AM; Johnson KC; Stan RV; Sanglikar A; Ahmed Y; Dmitrovsky E; Freemantle SJ
BMC Cancer; 2013 Apr; 13():211. PubMed ID: 23621985
[TBL] [Abstract][Full Text] [Related]
18. Macrocyclized Extended Peptides: Inhibiting the Substrate-Recognition Domain of Tankyrase.
Xu W; Lau YH; Fischer G; Tan YS; Chattopadhyay A; de la Roche M; Hyvönen M; Verma C; Spring DR; Itzhaki LS
J Am Chem Soc; 2017 Feb; 139(6):2245-2256. PubMed ID: 28084734
[TBL] [Abstract][Full Text] [Related]
19. Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics.
Nkizinkiko Y; Suneel Kumar BVS; Jeankumar VU; Haikarainen T; Koivunen J; Madhuri C; Yogeeswari P; Venkannagari H; Obaji E; Pihlajaniemi T; Sriram D; Lehtiö L
Bioorg Med Chem; 2015 Aug; 23(15):4139-4149. PubMed ID: 26183543
[TBL] [Abstract][Full Text] [Related]
20.
Loganathan L; Muthusamy K; Jayaraj JM; Kajamaideen A; Balthasar JJ
J Biomol Struct Dyn; 2019 Sep; 37(14):3637-3648. PubMed ID: 30204055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]